Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

December 24th 2024

Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.

EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

January 3rd 2025

Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.

EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

January 7th 2025

Panelists discuss how patient selection for quadruplet therapy in transplant-ineligible/deferred NDMM requires careful consideration of multiple factors, including fitness level and comorbidities, while highlighting daratumumab-VRd’s potential advantages such as subcutaneous administration and demonstrated efficacy in the CEPHEUS trial despite increased complexity and cost considerations.

EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

January 14th 2025

Panelists discuss how the future treatment landscape for transplant-ineligible/deferred NDMM is evolving toward more personalized approaches with quadruplet regimens, while acknowledging remaining challenges in optimizing duration of therapy, managing toxicities, and improving access to novel combinations.

EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM

January 21st 2025

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.